Cargando…
Sustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
Autores principales: | Ascarateil, Stephane, Puget, Aude, Gaucheron, Jerome, Koziol, Marie-Eve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652544/ http://dx.doi.org/10.1186/2051-1426-3-S2-P429 |
Ejemplares similares
-
Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015) -
Evaluation of Montanide™ ISA 71 VG Adjuvant during Profilin Vaccination against Experimental Coccidiosis
por: Jang, Seung I., et al.
Publicado: (2013) -
Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with Chlamydia muridarum
por: Pal, Sukumar, et al.
Publicado: (2023) -
A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis
por: Ricciardi, Alessandra, et al.
Publicado: (2016) -
Immune System Modulation by the Adjuvants Poly (I:C) and Montanide ISA 720
por: Marques, Rodolfo F., et al.
Publicado: (2022)